Carlyle Group will purchase a 20% stake in Indian billionaire Ajay Piramal’s pharmaceutical business, according to an exchange filing.
The private equity fund will pay $490 million for the holding, valuing the business at an enterprise value of $2.7 billion. In addition to helping expand capacity of the pharmaceutical operations, the Piramal group will use the money to repay some of parent Piramal Enterprises Ltd.’s debt, the filing said.
“This infusion of funds will further strengthen our balance sheet and provide us with a war chest for the next phase of our strategy,” Ajay Piramal, chairman of Piramal Enterprises, said in the filing.
In May, Carlyle agreed to buy up to 74% of SeQuent Scientific, the largest pure-play animal healthcare company in India.
Source: Bloomberg
Can’t stop reading? Read more
TPG explores $7.5bn Asia OneHealthcare exit with sale or IPO options
TPG explores $7.5bn Asia OneHealthcare exit with sale or IPO options TPG has appointed Malayan...
Blackstone teams with Dubai Aerospace on $1.6bn annual aircraft leasing push
Blackstone teams with Dubai Aerospace on $1.6bn annual aircraft leasing push Blackstone has...
CVC seeks co-investors for $12.7bn Recordati buyout in mega LBO push
CVC seeks co-investors for $12.7bn Recordati buyout in mega LBO push CVC Capital Partners is...